The DOI matches its Crossref record.
Imiquimod, a Patient-Applied Immune-Response Modifier for Treatment of External Genital Warts
Open accessAbstract
Genital human papillomavirus infection is one of the most common sexually transmitted diseases. Imiquimod is a new agent, an immune-response modifier, that has been demonstrated to have potent in vivo antiviral and antitumor effects in animal models. The present prospective, multicenter, double-blind, randomized, vehicle-controlled trial evaluated the efficacy and safety of daily patient-applied imiquimod for up to 16 weeks for the treatment of external genital warts. Wart recurrence was investigated during a 12-week treatment-free follow-up period. In the intent-to-treat analysis, baseline warts cleared from 49 of 94 (52%) patients treated with 5% imiquimod cream, 13 of 90 (14%) patients treated with 1% imiquimod cream, and 3 of 95 (4%) vehicle-treated patients; the differences between the groups treated with vehicle and imiquimod were significant (P< 0.0001). For subjects who completed the follow-up period, recurrence rates after a complete response were 19% (9 of 48 patients) in the 5% imiquimod cream group, 17% (2 of 12) in the 1% imiquimod cream group, and 0% (0 of 3) in the vehicle-treated group. There were no systemic reactions, although local skin reactions (generally of mild or moderate severity) were common, particularly in the 5% imiquimod cream group. Local reactions caused two patients to discontinue treatment. The most frequently reported local skin reactions were erythema, excoriation or flaking, and erosion. Patient-applied 5% imiquimod cream is effective for the treatment of external genital warts and has a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Interferons at age 50: past, current and future impact on biomedicine
Borden, E. C., Sen, G. C., Uze, G., Silverman, R. H., Ransohoff, R. M., Foster, G. R., & Stark, G. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2422 · Cited by 1,154
TLR7 Ligands Induce Higher IFN-α Production in Females
Berghöfer, B., Frommer, T., Haley, G., Fink, L., Bein, G., & Hackstein, H. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.4.2088 · Cited by 480
Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug
Miller, R. L., Gerster, J. F., Owens, M. L., Slade, H. B., & Tomai, M. A. (1999) · International Journal of Immunopharmacology · doi:10.1016/s0192-0561(98)00068-x · Cited by 417
Self-citationTreatment of Vulvar Intraepithelial Neoplasia with Topical Imiquimod
van Seters, M., van Beurden, M., ten Kate, F. J. W., Beckmann, I., Ewing, P. C., Eijkemans, M. J. C., Kagie, M. J., Meijer, C. J. M., Aaronson, N. K., KleinJan, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa072685 · Cited by 398
Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential
Stanley, M. A. (2002) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2002.01151.x · Cited by 377
Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream
Beutner, K. R., Geisse, J. K., Helman, D., Fox, T. L., Ginkeld, A., & Owens, M. L. (1999) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(99)70261-6 · Cited by 363
Self-citationExternal Genital Warts: Diagnosis, Treatment, and Prevention
Wiley, D. J., Douglas, J., Beutner, K., Cox, T., Fife, K., Moscicki, A., & Fukumoto, L. (2002) · Clinical Infectious Diseases · doi:10.1086/342109 · Cited by 354
Self-citationTrends and strategies to combat viral infections: A review on FDA approved antiviral drugs
Tompa, D. R., Immanuel, A., Srikanth, S., & Kadhirvel, S. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.01.076 · Cited by 257
Abt, M. C., Buffie, C. G., Sušac, B., Becattini, S., Carter, R. A., Leiner, I., Keith, J. W., Artis, D., Osborne, L. C., & Pamer, E. G. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6663 · Cited by 94
Metadata
- Authors
- Beutner, K. R., Tyring, S. K., Trofatter, K. F., Douglas, J. M., Spruance, S., Owens, M. L., Fox, T. L., Hougham, A. J., & Schmitt, K. A.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-04
- Volume
- 42
- Issue
- 4
- Pages
- 789-794
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2154197499
- Cited by
- 225
- References
- 0
- FWCI
- 17.76
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.